Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future 

Tackling Uncommon EGFR mutations: Efficacy of EGFR TKIs in NSCLC

Date

22 Nov 2020

Session

Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future 

Presenters

Hiroshi Tanaka

Authors

H. Tanaka

Author affiliations

  • Department Of Internal Medicine, Niigata Cancer Center Hospital, Niigata/JP
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings